194 related articles for article (PubMed ID: 29298345)
1. Redox modulation of NQO1.
Siegel D; Dehn DD; Bokatzian SS; Quinn K; Backos DS; Di Francesco A; Bernier M; Reisdorph N; de Cabo R; Ross D
PLoS One; 2018; 13(1):e0190717. PubMed ID: 29298345
[TBL] [Abstract][Full Text] [Related]
2. A redox-mediated conformational change in NQO1 controls binding to microtubules and α-tubulin acetylation.
Siegel D; Bersie S; Harris P; Di Francesco A; Armstrong M; Reisdorph N; Bernier M; de Cabo R; Fritz K; Ross D
Redox Biol; 2021 Feb; 39():101840. PubMed ID: 33360352
[TBL] [Abstract][Full Text] [Related]
3. The NQO1 bioactivatable drug, β-lapachone, alters the redox state of NQO1+ pancreatic cancer cells, causing perturbation in central carbon metabolism.
Silvers MA; Deja S; Singh N; Egnatchik RA; Sudderth J; Luo X; Beg MS; Burgess SC; DeBerardinis RJ; Boothman DA; Merritt ME
J Biol Chem; 2017 Nov; 292(44):18203-18216. PubMed ID: 28916726
[TBL] [Abstract][Full Text] [Related]
4. Development of beta-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:quinone oxidoreductase 1 levels.
Reinicke KE; Bey EA; Bentle MS; Pink JJ; Ingalls ST; Hoppel CL; Misico RI; Arzac GM; Burton G; Bornmann WG; Sutton D; Gao J; Boothman DA
Clin Cancer Res; 2005 Apr; 11(8):3055-64. PubMed ID: 15837761
[TBL] [Abstract][Full Text] [Related]
5. An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis.
Huang X; Dong Y; Bey EA; Kilgore JA; Bair JS; Li LS; Patel M; Parkinson EI; Wang Y; Williams NS; Gao J; Hergenrother PJ; Boothman DA
Cancer Res; 2012 Jun; 72(12):3038-47. PubMed ID: 22532167
[TBL] [Abstract][Full Text] [Related]
6. NAD(P)H-dependent quinone oxidoreductase 1 (NQO1) and cytochrome P450 oxidoreductase (CYP450OR) differentially regulate menadione-mediated alterations in redox status, survival and metabolism in pancreatic β-cells.
Gray JP; Karandrea S; Burgos DZ; Jaiswal AA; Heart EA
Toxicol Lett; 2016 Nov; 262():1-11. PubMed ID: 27558805
[TBL] [Abstract][Full Text] [Related]
7. Enhanced activation of NAD(P)H: quinone oxidoreductase 1 attenuates spontaneous hypertension by improvement of endothelial nitric oxide synthase coupling via tumor suppressor kinase liver kinase B1/adenosine 5'-monophosphate-activated protein kinase-mediated guanosine 5'-triphosphate cyclohydrolase 1 preservation.
Kim YH; Hwang JH; Kim KS; Noh JR; Gang GT; Oh WK; Jeong KH; Kwak TH; Choi HS; Lee IK; Lee CH
J Hypertens; 2014 Feb; 32(2):306-17. PubMed ID: 24241058
[TBL] [Abstract][Full Text] [Related]
8. NAD(P)H:quinone oxidoreductase 1 (NQO1) localizes to the mitotic spindle in human cells.
Siegel D; Kepa JK; Ross D
PLoS One; 2012; 7(9):e44861. PubMed ID: 22984577
[TBL] [Abstract][Full Text] [Related]
9. Mechanistic studies of cancer cell mitochondria- and NQO1-mediated redox activation of beta-lapachone, a potentially novel anticancer agent.
Li JZ; Ke Y; Misra HP; Trush MA; Li YR; Zhu H; Jia Z
Toxicol Appl Pharmacol; 2014 Dec; 281(3):285-93. PubMed ID: 25448047
[TBL] [Abstract][Full Text] [Related]
10. Tumor-selective, futile redox cycle-induced bystander effects elicited by NQO1 bioactivatable radiosensitizing drugs in triple-negative breast cancers.
Cao L; Li LS; Spruell C; Xiao L; Chakrabarti G; Bey EA; Reinicke KE; Srougi MC; Moore Z; Dong Y; Vo P; Kabbani W; Yang CR; Wang X; Fattah F; Morales JC; Motea EA; Bornmann WG; Yordy JS; Boothman DA
Antioxid Redox Signal; 2014 Jul; 21(2):237-50. PubMed ID: 24512128
[TBL] [Abstract][Full Text] [Related]
11. Distinct responses of compartmentalized glutathione redox potentials to pharmacologic quinones targeting NQO1.
Kolossov VL; Ponnuraj N; Beaudoin JN; Leslie MT; Kenis PJ; Gaskins HR
Biochem Biophys Res Commun; 2017 Jan; 483(1):680-686. PubMed ID: 27986568
[TBL] [Abstract][Full Text] [Related]
12. Activation of NAD(P)H:quinone oxidoreductase ameliorates spontaneous hypertension in an animal model via modulation of eNOS activity.
Kim YH; Hwang JH; Noh JR; Gang GT; Kim DH; Son HY; Kwak TH; Shong M; Lee IK; Lee CH
Cardiovasc Res; 2011 Aug; 91(3):519-27. PubMed ID: 21502369
[TBL] [Abstract][Full Text] [Related]
13. β-lapachone-mediated WST1 Reduction as Indicator for the Cytosolic Redox Metabolism of Cultured Primary Astrocytes.
Watermann P; Dringen R
Neurochem Res; 2023 Jul; 48(7):2148-2160. PubMed ID: 36811754
[TBL] [Abstract][Full Text] [Related]
14. Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers.
Bey EA; Reinicke KE; Srougi MC; Varnes M; Anderson VE; Pink JJ; Li LS; Patel M; Cao L; Moore Z; Rommel A; Boatman M; Lewis C; Euhus DM; Bornmann WG; Buchsbaum DJ; Spitz DR; Gao J; Boothman DA
Mol Cancer Ther; 2013 Oct; 12(10):2110-20. PubMed ID: 23883585
[TBL] [Abstract][Full Text] [Related]
15. Sulindac compounds facilitate the cytotoxicity of β-lapachone by up-regulation of NAD(P)H quinone oxidoreductase in human lung cancer cells.
Kung HN; Weng TY; Liu YL; Lu KS; Chau YP
PLoS One; 2014; 9(2):e88122. PubMed ID: 24505400
[TBL] [Abstract][Full Text] [Related]
16. Prevention of salt-induced renal injury by activation of NAD(P)H:quinone oxidoreductase 1, associated with NADPH oxidase.
Kim YH; Hwang JH; Noh JR; Gang GT; Tadi S; Yim YH; Jeoung NH; Kwak TH; Lee SH; Kweon GR; Kim JM; Shong M; Lee IK; Lee CH
Free Radic Biol Med; 2012 Mar; 52(5):880-8. PubMed ID: 22227174
[TBL] [Abstract][Full Text] [Related]
17. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
Bey EA; Bentle MS; Reinicke KE; Dong Y; Yang CR; Girard L; Minna JD; Bornmann WG; Gao J; Boothman DA
Proc Natl Acad Sci U S A; 2007 Jul; 104(28):11832-7. PubMed ID: 17609380
[TBL] [Abstract][Full Text] [Related]
18. NAD(P)H:quinone oxidoreductase 1 determines radiosensitivity of triple negative breast cancer cells and is controlled by long non-coding RNA NEAT1.
Lin LC; Lee HT; Chien PJ; Huang YH; Chang MY; Lee YC; Chang WW
Int J Med Sci; 2020; 17(14):2214-2224. PubMed ID: 32922184
[TBL] [Abstract][Full Text] [Related]
19. NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones.
Siegel D; Yan C; Ross D
Biochem Pharmacol; 2012 Apr; 83(8):1033-40. PubMed ID: 22209713
[TBL] [Abstract][Full Text] [Related]
20. NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger.
Siegel D; Gustafson DL; Dehn DL; Han JY; Boonchoong P; Berliner LJ; Ross D
Mol Pharmacol; 2004 May; 65(5):1238-47. PubMed ID: 15102952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
